 Home > Active Ingredient News > Antitumor Therapy > Lancet: Segmentectomy is expected to become the standard procedure for small peripheral NSCLC!

Lancet: Segmentectomy is expected to become the standard procedure for small peripheral NSCLC!

 Last Update: 2022-05-20
 Source: Internet
 Author: User

Tags

1 cell phone

pro 3 5

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Lung cancer is the leading cause of cancer-related death worldwide, and its incidence continues to increase

The actual indication for sublobar resection has been extended to early stage lung cancer

This is a randomized, controlled, non-inferiority clinical trial that enrolled patients with clinical stage IA NSCHC (tumor diameter ≤2 cm, consolidation tumor ratio >0.

Between October 10, 2009, and October 21, 2014, a total of 1106 patients were recruited: 554 in the lobectomy group and 552 in the segmentectomy group

The 5-year overall survival rates in the segmentectomy and lobectomy groups were 94.

The 5-year recurrence-free survival rates of the segmentectomy and lobectomy groups were 88.

This study is the first phase 3 trial to demonstrate an overall survival benefit of segmentectomy versus lobectomy in patients with small peripheral NSCLC

Segmentectomy may become the standard surgical modality for such patients

Original source:

Hisashi Saji, et al.

Hisashi Saji, et al.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.
The Lancet.
April 23, 2022.
https://doi.
org/10.
1016/S0140-6736(21)02333-3.

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Bulk Peptides Kisspeptin 10 (human) /Kisspeptin 10/ Kisspeptin-10 Acetate CAS 374675-21-5

CAS No.: 374675-21-5

Pharmacy Grade

$10-13/UNIT FOB

Cediranib

CAS No.: 288383-20-0

$22/KG EXW

Upadacitinib hemihydrate API

CAS No.: 2050057-56-0

Pharmacy Grade

$35-45/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.